Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Participant Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 22, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

NCT07225556
View directory record Official record
Conditions
Overweight, Obesity
Interventions
LY4167586, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

NCT01571388
View directory record Official record
Conditions
Healthy, Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions
dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

NCT02650973
View directory record Official record
Conditions
Healthy
Interventions
CHS-1701, Pegfilgrastim
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Cypress, California • Cincinnati, Ohio • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

NCT02717754
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Little Rock, Arkansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

NCT07247942
View directory record Official record
Conditions
Healthy Subjects (HS)
Interventions
zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of New Magnetic Resonance Imaging Methods of the Brain

NCT00004577
View directory record Official record
Conditions
Healthy Volunteer, Magnetic Resonance Imaging, Healthy, fMRI, Brain Mapping, Adult
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

NCT06262477
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB800, Actemra
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

NCT01247272
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Hydrochloride, PROZAC WEEKLY®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Dilworth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

NCT01519531
View directory record Official record
Conditions
Drug Safety
Interventions
Placebo, VIA-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

NCT00647972
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine Tablets 20 mg, Zyprexa® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

NCT03827629
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00001673
View directory record Official record
Conditions
Alcoholic Intoxication, Alcoholism, Healthy
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
2,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

NCT00649129
View directory record Official record
Conditions
Healthy
Interventions
Oxybutynin Chloride ER Tablets 10 mg, Ditropan XL® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

NCT02893488
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 22, 2026, 2:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

NCT04928703
View directory record Official record
Conditions
Healthy
Interventions
Ketamine
Drug
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 2:34 PM EDT